10-Q: Indivior PLC Reports Q1 2025 Results: Revenue Declines Amidst Increased Competition

Indivior PLC's Q1 2025 net revenue decreased by 6% year-over-year to $266 million, primarily due to increased competition affecting SUBOXONE Film sales in the U.S.

Summary

• Indivior PLC reported a net revenue of $266 million for the three months ended March 31, 2025, a decrease of 6% compared to $284 million in the same period of 2024.
• The decrease in revenue was primarily driven by increased competitive activity affecting SUBOXONE Film sales in the U.S.
• U.S. net revenue decreased by 8% to $222 million, while revenue from the Rest of the World increased by 3% to $44 million.
• SUBLOCADE net revenue in the U.S. decreased by 3% to $163 million.
• Cost of sales increased by 16% to $44 million, and gross margin decreased to 83% from 87%.
• Selling, general, and administrative expenses decreased by 8% to $132 million, reflecting streamlining actions.
• Research and development expenses decreased by 19% to $22 million due to a refocus of the development pipeline.
• Net income was $47 million, compared to $61 million in the prior year period.
• Basic and diluted earnings per share were $0.38, compared to $0.45 in the prior year period.
• The company's effective tax rate was 19% compared to 16% in the prior year period.
• Net cash provided by operating activities was $75 million, compared to net cash used in operating activities of $37 million in the prior year period.
• The company expects capital expenditures of $50 million to $70 million in 2025, primarily to finalize the SUBLOCADE suite at the Raleigh Manufacturing Facility.
• The estimated last subject last visit for the Phase 2 proof of concept study for INDV-2000 is now expected in the first half of 2026, delayed from late 2025 due to lower enrollment rates.

Sentiment

Score: 5

Explanation: The sentiment is neutral. While there are positive aspects such as decreased operating expenses and increased cash from operations, the overall financial performance shows a decline in revenue and net income due to increased competition. The delay in the INDV-2000 study is also a negative factor.

Positives

• Rest of the World net revenue increased by 3% to $44 million.
• Selling, general, and administrative expenses decreased by 8% due to streamlining actions.
• Research and development expenses decreased by 19% due to a refocus of the development pipeline.
• Net cash provided by operating activities increased by $112 million to $75 million.
• The FDA approved label changes for SUBLOCADE, including a rapid initiation protocol and alternative injection sites.

Negatives

• Net revenue decreased by 6% to $266 million.
• U.S. net revenue decreased by 8% to $222 million.
• SUBLOCADE net revenue in the U.S. decreased by 3% to $163 million.
• Gross margin decreased to 83% from 87%.
• Net income decreased to $47 million from $61 million.
• The estimated last subject last visit for the Phase 2 proof of concept study for INDV-2000 is now expected in the first half of 2026, delayed from late 2025 due to lower enrollment rates.

Risks

• Increased competitive activity is impacting SUBOXONE Film sales in the U.S.
• Unfavorable pricing and channel mix are affecting SUBLOCADE revenue.
• Potential impact of tariffs on pharmaceutical products and raw materials.
• The company's current liabilities exceed its current assets by $122 million, and total liabilities exceed total assets by $285 million.
• The company is subject to contingent liabilities related to ongoing legal proceedings.

Future Outlook

The company expects gross margin to continue in the low-to-mid 80 percent range for the remainder of 2025. Research and development expenses are expected to continue to track below 2024 levels throughout 2025. The company believes its existing cash and cash equivalents and investments together with cash generated from operations and debt will enable its anticipated cash needs to be met for at least the twelve-month period following the issuance of this Form 10-Q.

Industry Context

The report indicates increased competitive activity in the opioid dependence treatment market, particularly affecting SUBOXONE Film sales. This suggests a dynamic market landscape where pricing pressures and market share shifts are significant factors.

Comparison to Industry Standards

• The report does not provide specific comparisons to industry standards or competitors.
• However, the mention of increased competitive activity suggests that Indivior is facing challenges from generic and branded competitors in the opioid dependence treatment market.
• Companies like Teva Pharmaceuticals, Mylan (now Viatris), and Dr. Reddy's Laboratories are key players in the generic suboxone film market.
• Alkermes, with its Vivitrol injection, is a competitor in the long-acting injectable market for opioid dependence treatment.
• The report's focus on SUBLOCADE and OPVEE indicates a strategic shift towards long-acting injectables and overdose reversal products, aligning with broader trends in addiction treatment.

Legal Proceedings

• The Company has been named as a defendant in more than 400 civil lawsuits alleging that manufacturers, distributors, and retailers of opioids engaged in a longstanding practice to market opioids as safe and effective for the treatment of long-term chronic pain to increase the market for opioids and their own market shares for opioids, or alleging individual personal injury claims.
• The Company has been named as a defendant in numerous lawsuits alleging that SUBOXONE Film was defectively designed and caused dental injury, and that the Company failed to properly warn of the risks of such injuries.
• Certain shareholders issued representative and multiparty claims against Indivior PLC in the High Court of Justice for the Business and Property Courts of England and Wales, Kings Bench Division, alleging that Indivior PLC violated the U.K. Financial Services and Markets Act 2000 (FSMA 2000) by making false or misleading statements or material omissions in public disclosures, including the 2014 Demerger Prospectus, regarding an alleged product-hopping scheme regarding the switch from SUBOXONE Tablets to SUBOXONE Film.
• A class action lawsuit was filed against Indivior PLC, Mark Crossley (the CEO of the Company), and Ryan Preblick (the CFO of the Company) on August 2, 2024, alleging violations of certain U.S. federal securities laws, and the lead plaintiff filed an amended complaint on December 5, 2024 which also named Richard Simkin (the CCO of the Company) as a defendant.
• On November 8, 2023, plaintiff James Litten filed a class action complaint in the Delaware Court of Chancery alleging that former officers and directors of Opiant Pharmaceuticals, Inc. breached fiduciary duties of care, loyalty, and good faith in connection with Indivior PLC's 2022 acquisition of Opiant.

Stakeholder Impact

• Shareholders may be concerned about the decrease in revenue and net income.
• Employees may be affected by streamlining actions and the refocus of the development pipeline.
• Patients may benefit from the FDA approval of label changes for SUBLOCADE, including a rapid initiation protocol and alternative injection sites.
• The company's ability to meet its obligations in the long term depends on sustaining sales volume performance and managing collections and rebate payments.

Next Steps

• The company will continue to focus on sales volume performance and managing collections and rebate payments to maintain liquidity.
• The company will continue investing in development stage assets from time to time, with no current commitments.
• The company will finalize the SUBLOCADE suite at the Raleigh Manufacturing Facility.
• The company will continue to evaluate and defend itself in ongoing legal proceedings.

Key Dates

Keywords

SUBLOCADE, SUBOXONE Film, Opioid Use Disorder, Net Revenue, Financial Results, Indivior PLC, PERSERIS, OUD, Q1 2025